Overview

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Status:
Recruiting
Trial end date:
2023-11-20
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
Phase:
Phase 2
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Gemcitabine
Paclitaxel